Legal status in the United States
Is Tesamorelin legal?
Read at FDA, DEA and WADAPublished by PepVault
Tesamorelin is FDA-approved (Egrifta, first in 2010), is not a federally controlled substance, and is banned in sport (WADA names it under S2.2.4), as of November 18, 2026.
Tesamorelin at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Egrifta, 2010) |
| Compounding | A biologic; FDA: not eligible for 503A or 503B |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned, named (S2.2.4) |
FDA approval
Tesamorelin is FDA-approved as Egrifta, first in 2010, for one use: belly fat in adults with HIV and lipodystrophy.
Egrifta (injection)
Approved for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss). BLA 022505, first approved November 10, 2010.
- Drugs@FDA: Egrifta, application 022505, U.S. Food and Drug Administration. Read .
- Egrifta WR prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Egrifta, application 022505, U.S. Food and Drug Administration. Read .

Compounding
Drugs@FDA lists tesamorelin as a biologic (BLA 022505, Egrifta), and FDA writes that biological products “are not eligible for the exemptions for compounded drugs under sections 503A and 503B”.
The source: “Biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FD&C Act.”
- Compounding and the FDA: Questions and Answers (content current as of September 16, 2025), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans tesamorelin at all times, in and out of competition: the 2026 list names it under S2.2.4, growth hormone releasing factors.
The source: “growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Tesamorelin in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Tesamorelin FDA approved?
Tesamorelin is FDA-approved as Egrifta, first in 2010, for one use: belly fat in adults with HIV and lipodystrophy.
Is Tesamorelin a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Tesamorelin banned in sport?
WADA bans tesamorelin at all times, in and out of competition: the 2026 list names it under S2.2.4, growth hormone releasing factors.
What does FDA say about compounding Tesamorelin?
Drugs@FDA lists tesamorelin as a biologic (BLA 022505, Egrifta), and FDA writes that biological products “are not eligible for the exemptions for compounded drugs under sections 503A and 503B”.